A transient ischemic attack, also known as TIA, can be a warning sign of a major stroke. A transient ischemic attack (TIA) is a type of stroke that lasts only for a short period of time. Typically, it can last anywhere from a few minutes to an hour and resolves completely without leaving any permanent damage. TIA is caused by temporary blockage in a blood vessel that supplies the brain, just like a full-fledged stroke. During a TIA, people may experience temporary loss of vision, numbness, weakness, or loss of sensation on one side of the body, slurred speech, and confusion. Like a stroke, TIA is a medical emergency. TIA is characterized by sudden onset of neurological symptoms. It is important to recognize a TIA, because it is warning sign that an individual is at higher risk for a full-fledged stroke in the next 24 hours. A person presenting with symptoms of TIA should seek immediate medical care. The physician will confirm the diagnosis with medical history, physical and neurological examination, and imaging tests such as computed tomography, magnetic resonance imaging, or angiography. Treatment for TIA should be directed at preventing a major stroke and preventing future events from occurring. Treatment may include medications such as antiplatelet drugs and anticoagulants, lifestyle modifications with regard to risk factors, and evaluation for possible surgical interventions. It is important to reduce risk factors, such as smoking, excessive alcohol use, high cholesterol levels, and high blood pressure. It is important to recognize the signs and symptoms of a TIA and to seek immediate medical care. The prompt diagnosis and treatment of TIA can reduce the risk of developing a full-fledged stroke, and reduce the risk of paralysis, speech, and language impairments, and death associated with stroke. Early diagnosis and treatment can improve the outcomes associated with TIA and stroke.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States